New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2014
09:14 EDTTWTR, STZ, TCS, MU, MCD, TEVA, PATH, JCP, RAD, FRX, MSFT, F, ENDPOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Micron (MU), up 10%... Constellation Brands (STZ), up 7%... Apollo Education (APOL), up 8%. ALSO HIGHER: Forest Laboratories (FRX), up 14% after acquiring Aptalis for $2.9B in cash... Rite Aid (RAD), up 2.6% following upgrade at JPMorgan... NuPathe (PATH), up 36% after receiving takeover bid from Teva (TEVA) to rival formerly agreed to deal with Endo Health (ENDP)... Ford (F), up 1.6% after AP says CEO Mulally staying at Ford. Microsoft (MSFT), down 0.6% after the news, as Mulally was viewed as a candidate for its CEO opening... ALSO LOWER: The Container Store (TCS), down 10.4% after earnings, downgrade at BofA Merrill Lynch... J.C. Penney (JCP), down 6.3% after backing Q4 outlook but not providing December same-store sales figure... Twitter (TWTR), down 4% following downgrade at Cantor... McDonald's (MCD), down 1% following downgrade at Wells Fargo.
News For TWTR;F;MSFT;FRX;RAD;JCP;PATH;TEVA;MCD;MU;TCS;STZ;ENDP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | all recent news | >>
October 8, 2014
11:05 EDTJCPJ.C. Penney falls 6%, halted for circuit-breaker after providing guidance
Subscribe for More Information
11:03 EDTJCPJ.C. Penney now sees Q3 SSS up low single digits vs. previous guidance
Subscribe for More Information
11:01 EDTJCPJ.C. Penney says has seen slow down in sales in September
Subscribe for More Information
11:00 EDTJCPJ.C. Penney reaffirms all FY guidance metrics
Subscribe for More Information
10:59 EDTJCPJ.C. Penney sees $14.5B in total sales by 2017
CFO Ed Record says focused on restoring profitability. Says since 4Q13, has had three straight quarters of sales growth. Sees opportunities to improve SG&A and gross margin. Sees $3.5B sales growth opportunity over next three years: Sees continued share growth a $1M opportunity over three years, center core a $1M opportunity, home store a $750M opportunity, omnichannel a $800M opportunity. Sees $1.2B EBITDA growth opportunity over next three years. Sees sales growth in mid single digits through 2017. Free cash flow over next three years "at least" $600M. Comments made at J.C. Penney's Analyst Day.
10:33 EDTJCPJ.C. Penney says seeing "significant" shift to mobile
Subscribe for More Information
10:33 EDTFFord falls to fresh 52-week low, levels to watch
The shares are down 2% at time of writing to $13.82, just above the fresh 52-week low set earlier today at $13.76. Support below today's low is at $13.36. Resistance is at the session high at $14.10.
10:25 EDTJCPJ.C. Penney says home is $750M growth opportunity
Subscribe for More Information
10:00 EDTMUOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:38 EDTTWTRActive equity options trading on open
Subscribe for More Information
09:20 EDTJCPJ.C. Penney says will expand Disney stops in stores to 680 from 500
09:20 EDTJCPJ.C. Penney CEOsays will open more Sephora shops in store
Subscribe for More Information
09:20 EDTJCPOn The Fly: Pre-market Movers
Subscribe for More Information
08:18 EDTJCPJ.C. Penney CEO Ullman says customers remain cautious
Subscribe for More Information
08:05 EDTTEVATeva initiates NDA submission to FDA for CEP-33237
Teva Pharmaceutical announced the initiation of a rolling New Drug Application submission to the U.S. Food and Drug Administration for hydrocodone bitartrate extended-release tablets designed with Teva’s proprietary technology providing potential abuse-deterrent properties CEP-33237 as allowed for fast track designated products. Teva expects to complete the NDA submission by the end of 2014. Teva also announced positive results from a nasal Human Abuse Liability study which supports the NDA. The nasal HAL study found that in nondependent, recreational opioid users, abuse potential for crushed intranasal CEP-33237 was significantly lower than intranasal immediate-release hydrocodone. Teva has now completed positive HAL studies in the two most common routes of hydrocodone abuse, oral and intranasal. CEP-33237 demonstrated a safety profile in the Phase III study that is consistent with the known safety profile of hydrocodone and other opioid analgesic therapies. Adverse events reported in 5% or more of hydrocodone-treated patients during either the titration or double-blind treatment periods included nausea, constipation, vomiting, headache, somnolence and dizziness.
07:43 EDTMUMicron initiated with a Neutral at Ladenburg
Subscribe for More Information
07:28 EDTMCDMcDonald's brand solid but execution issues remain, says UBS
Subscribe for More Information
06:47 EDTTEVALawmakers may push for new regulations on generic drug makers, NY Times says
After the prices of some generic drugs soared more than 1,000% over the last year, two influential members of Congress are probing the sector and threatening to look to impose new regulations on it, according to The New York Times. Generic drug makers include Teva (TEVA), Mylan (MYL), Actavis (ACT), and Lannett (LCI).Reference Link
06:13 EDTMSFTNon-Apple notebook, tablet demand to be weak till 2Q15, DigiTimes reports
Demand for non-Apple (AAPL) notebooks and tablets may remain weak until the second quarter of 2015, reports DigiTimes. Citing Taiwan makers, the pressure due to booming sales from Apple products may decrease sales until Microsoft (MSFT) launches Windows 10 next year. Demand for Samsung (SSNLF), Sony (SNE) , And HTC smartphones have also dropped worldwide recently. Reference Link
06:00 EDTTWTRInstagram still most used social network for teens, says Piper Jaffray
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use